Mesothelioma.com Resources for Patients and their Families
Request Free Guide

Mesothelioma Doctors

Shirish M. Gadgeel, MD

Dr. Gadgeel
Ann Arbor, MI

Dr. Shirish M. Gadgeel

Medical Oncologist

University of Michigan

Rogel Cancer Center
1500 East Medical Center Drive
Floor B1, Reception E

Ann Arbor, MI 48109
734.647.8902

Need Help Contacting This Doctor?

Dr. Gadgeel joined Michigan Medicine in 2017 where he currently serves as the Mary Lou Kennedy Research Professor in Thoracic Oncology and a professor in the Department of Internal Medicine’s Division of Hematology/Oncology. Dr. Gadgeel sees patients at both the University of Michigan Rogel Cancer Center in Ann Arbor and the Northville Health Center, with the belief that by expanding his geographic treatment area, he can include a greater number of patients in clinical trials for innovative lung cancer therapies.

In his research, Dr. Gadgeel conducts clinical trials in search of new treatment options for lung cancer, including mesothelioma. One of Dr. Gadgeel's studies targeted new chemotherapy options for patients with peritoneal mesothelioma, or mesothelioma of the abdominal walls. His research has been supported with grants from the National Cancer Institute, the SWOG Cancer Research Network, universities, and pharmaceutical companies.

Widely published in numerous peer-reviewed journals, Dr. Gadgeel is on the editorial boards for the journals Cancer and Clinical Lung Cancer. He also serves on the executive committee for lung cancer at SWOG.

Main Specialty: Oncology

Other Interests & Specialties: General oncology, hematologic oncology, drug development for lung cancer and thoracic cancers.

Certifications, Awards & Accolades: American Board of Internal Medicine Certification in Internal Medicine, American Board of Internal Medicine Certification in Medical Oncology, member of the American Society of Clinical Oncology (ASCO), member of the International Association for the Study of Lung Cancer (IASLC)

Education & Experience:

Publications:
Phase II Study of Cediranib in Patients with Malignant Pleural Mesothelioma. Journal of Thoracic Oncology. November 2011;6(11):1938-45. doi: 10.1097/JTO.0b013e318229586e

Plasma Biomarker Enrichment of Clinical Prognostic Indices in Malignant Pleural Mesothelioma. Journal of Thoracic Oncology. June 2016;11(6):900-9. doi: 10.1016/j.jtho.2016.02.006

Mesothelioma in the United States: a Surveillance, Epidemiology, and End Results (SEER)-Medicare investigation of treatment patterns and overall survival. Clinical Epidemiology. October 2016;8:743-750. doi: 10.2147/CLEP.S105396

Novel combinations using pemetrexed in malignant mesothelioma. Clinical Lung Cancer. 2004 April 2004;5(2):S61-6.

Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial. The Journal of Clinical Oncology. July 2008;26(21):3567-72. doi: 10.1200/JCO.2007.15.2868

A finalized phase II report of pemetrexed (P) plus gemcitabine (G) as front-line chemotherapy for patients with peritoneal mesothelioma (PM). Journal of Clinical Oncology. June 2006;24:18S - Abstract 2050.

Author: Linda Molinari

Editor in Chief, Mesothelioma Cancer Alliance

Linda Molinari

Reviewer: Annette Charlevois

Patient Support Coordinator

Annette Charlevois
Share
Tweet
Share
Mesothelioma Treatment Guide

Free Mesothelioma Treatment Guide

Please fill in the form below to request our FREE Mesothelioma Treatment Guide. It will be sent to you within 24 hours.

Have you or someone you know been diagnosed with mesothelioma?

Get Access To:

Legal Rights Information Guide Free Guide Request Free Guide Free Mesothelioma Guide Free 2019 Mesothelioma Guide